Transcenta Holding Limited (HKG:6628)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.250
+0.030 (2.46%)
May 2, 2025, 4:08 PM HKT
-29.78%
Market Cap 495.12M
Revenue (ttm) 11.98M
Net Income (ttm) -308.92M
Shares Out 405.84M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 374,500
Average Volume 722,496
Open 1.290
Previous Close 1.220
Day's Range 1.160 - 1.290
52-Week Range 0.500 - 2.220
Beta 0.07
RSI 45.44
Earnings Date May 29, 2025

About Transcenta Holding

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST005, a PD-L1/TGF-β bi-functional protein candidate for solid tumors; TST002... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 184
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6628
Full Company Profile

Financial Performance

In 2024, Transcenta Holding's revenue was 11.26 million, a decrease of -79.09% compared to the previous year's 53.85 million. Losses were -290.29 million, -37.24% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.